At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Pre-Mkt 01-13 04:45:50 EST
0.2420
+0.0170
+7.56%
High0.2420Low0.2220Vol1.82M
Open0.2390D1 Closing0.2250Amplitude8.89%
Mkt Cap2.45MTradable Cap1.42MTotal Shares10.12M
T/O420.40KT/O Rate31.04%Tradable Shares5.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

GRI Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis
Reuters  ·  01-08
GRI Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis
GRI Bio Announces Additional Positive Data From Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
THOMSON REUTERS  ·  01-08
GRI Bio Announces Additional Positive Data From Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio Inc: GRI-0621 Continues to Demonstrate a Compelling Profile, Combining Favorable Safety and Tolerability
THOMSON REUTERS  ·  01-08
GRI Bio Inc: GRI-0621 Continues to Demonstrate a Compelling Profile, Combining Favorable Safety and Tolerability
SM launches free MSME sustainability learning program
prnewswire  ·  2025-12-23
SM launches free MSME sustainability learning program
China Insurance Association Publishes "Guidelines for Environmental, Social, and Governance Disclosure by Insurance Institutions: Interpretations and Case Studies"
Deep News  ·  2025-12-16
China Insurance Association Publishes "Guidelines for Environmental, Social, and Governance Disclosure by Insurance Institutions: Interpretations and Case Studies"
GRI Bio Announces Closing of $8.0 Million Public Offering
GlobeNewswire  ·  2025-12-13
GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GlobeNewswire  ·  2025-12-11
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
BUZZ-GRI Bio jumps as experimental lung drug shows promise in mid-stage trial
Reuters  ·  2025-12-11
BUZZ-GRI Bio jumps as experimental lung drug shows promise in mid-stage trial
GRI Bio Announces Positive Topline Data From Its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“Ipf”)
THOMSON REUTERS  ·  2025-12-11
GRI Bio Announces Positive Topline Data From Its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“Ipf”)
GRI Bio Inc - No Safety Concerns Observed in Subjects Enrolled at 12 Weeks of Treatment
THOMSON REUTERS  ·  2025-12-11
GRI Bio Inc - No Safety Concerns Observed in Subjects Enrolled at 12 Weeks of Treatment
GRI Bio Inc: Phase 2a Study Met Its Secondary Endpoints and Demonstrated Improvement in Biomarkers of Collagen Turnover
THOMSON REUTERS  ·  2025-12-11
GRI Bio Inc: Phase 2a Study Met Its Secondary Endpoints and Demonstrated Improvement in Biomarkers of Collagen Turnover
GRI Bio Inc: Phase 2a Study Also Met Exploratory Endpoints
THOMSON REUTERS  ·  2025-12-11
GRI Bio Inc: Phase 2a Study Also Met Exploratory Endpoints
GRI Bio Inc - Study Shows GRI-0621 Well Tolerated Over 12 Weeks
THOMSON REUTERS  ·  2025-12-11
GRI Bio Inc - Study Shows GRI-0621 Well Tolerated Over 12 Weeks
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire  ·  2025-12-11
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing
Reuters  ·  2025-12-08
BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing
GRI Bio Inc - Trial Meets Primary Endpoint & Certain Secondary Endpoints; GRI-0621 Well Tolerated - SEC Filing
THOMSON REUTERS  ·  2025-12-08
GRI Bio Inc - Trial Meets Primary Endpoint & Certain Secondary Endpoints; GRI-0621 Well Tolerated - SEC Filing
Gri Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis
Reuters  ·  2025-12-08
Gri Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis
GRI Bio Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  2025-12-08
GRI Bio Is Maintained at Buy by Ascendiant Capital
Gri Bio Faces Nasdaq Delisting Threat Over Equity Rule Violation
Reuters  ·  2025-12-02
Gri Bio Faces Nasdaq Delisting Threat Over Equity Rule Violation
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement
Deep News  ·  2025-11-19
China's First Specialized Policy on Green Trade Unveiled, Marking a New Phase of Systematic Advancement

Introduction

Company Name.
GRI BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.
Issue price:
--